Trade Royalty Pharma plc - RPRX CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
Trading Conditions
| Long position overnight fee | -0.0225% |
| Short position overnight fee | -0.0219% |
| Overnight fee time | 21:00 (UTC) |
| Min traded quantity | 1 |
| Currency | USD |
| Margin | 20% |
| Stock exchange | United States of America |
| Commission on trade | 0% |
*Information provided by Capital.com
Key Stats
| Prev. Close* | 44.3 |
| Open* | 43.78 |
| Day's Range* | 43.7 - 43.7 |
| 1-Year Change* | 13.27% |
| Volume | N/A |
| Average Vol. (3m) | 42.0861 |
| 52 wk Range | N/A |
| Market Cap | 26675.2 |
| P/E Ratio | 40.9249 |
| Shares Outstanding | 607220000 |
| Revenue | 2259.48 |
| EPS | 1.07343 |
| Dividend (Yield %) | 1.73003 |
| Beta | N/A |
| Next Earnings Date | Nov 8, 2022 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Aug 16, 2022 | 44.30 | 0.74 | 1.70% | 43.56 | 44.51 | 43.56 |
| Aug 15, 2022 | 43.88 | -0.10 | -0.23% | 43.98 | 44.26 | 43.65 |
| Aug 12, 2022 | 44.14 | 0.50 | 1.15% | 43.64 | 44.17 | 43.49 |
| Aug 11, 2022 | 43.67 | -0.10 | -0.23% | 43.77 | 44.08 | 43.46 |
| Aug 10, 2022 | 43.87 | 0.43 | 0.99% | 43.44 | 43.96 | 43.44 |
| Aug 9, 2022 | 43.61 | 0.35 | 0.81% | 43.26 | 43.90 | 43.09 |
| Aug 8, 2022 | 43.07 | 0.56 | 1.32% | 42.51 | 43.34 | 42.27 |
| Aug 5, 2022 | 42.40 | 0.13 | 0.31% | 42.27 | 43.51 | 42.25 |
| Aug 4, 2022 | 42.46 | 0.07 | 0.17% | 42.39 | 43.10 | 42.11 |
| Aug 3, 2022 | 42.77 | 0.32 | 0.75% | 42.45 | 42.95 | 42.45 |
| Aug 2, 2022 | 42.38 | -0.02 | -0.05% | 42.40 | 42.92 | 42.30 |
| Aug 1, 2022 | 42.72 | -0.62 | -1.43% | 43.34 | 43.39 | 42.59 |
| Jul 29, 2022 | 43.42 | 0.63 | 1.47% | 42.79 | 43.75 | 42.79 |
| Jul 28, 2022 | 43.53 | 0.06 | 0.14% | 43.47 | 43.95 | 42.78 |
| Jul 27, 2022 | 43.60 | 1.19 | 2.81% | 42.41 | 43.85 | 42.41 |
| Jul 26, 2022 | 42.94 | 0.83 | 1.97% | 42.11 | 43.33 | 42.11 |
| Jul 25, 2022 | 42.89 | -0.22 | -0.51% | 43.11 | 43.12 | 42.64 |
| Jul 22, 2022 | 43.18 | 0.71 | 1.67% | 42.47 | 43.38 | 42.40 |
| Jul 21, 2022 | 42.70 | -0.07 | -0.16% | 42.77 | 43.04 | 42.32 |
| Jul 20, 2022 | 42.96 | -0.53 | -1.22% | 43.49 | 43.71 | 42.77 |
Royalty Pharma plc Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Annual
- Quarterly
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Total revenue | 1597.93 | 1794.89 | 1814.25 | 2122.35 | 2289.46 |
| Revenue | 1597.93 | 1794.89 | 1814.25 | 2122.35 | 2289.46 |
| Total Operating Expense | 658.238 | 430.448 | -808.922 | 557.454 | 858.748 |
| Selling/General/Admin. Expenses, Total | 106.44 | 61.906 | 103.439 | 181.715 | 182.826 |
| Research & Development | 117.866 | 392.609 | 83.036 | 26.289 | 200.084 |
| Depreciation / Amortization | 33.267 | 33.267 | 23.924 | 23.058 | 22.996 |
| Other Operating Expenses, Total | 400.665 | -57.334 | -1019.32 | 295.892 | 452.842 |
| Operating Income | 939.692 | 1364.45 | 2623.18 | 1564.9 | 1430.71 |
| Interest Income (Expense), Net Non-Operating | 352.353 | 154.927 | -162.15 | 139.376 | -183.836 |
| Gain (Loss) on Sale of Assets | 52.753 | 0 | 0 | ||
| Other, Net | -1.618 | -1.518 | 0.393 | -2.321 | -5.678 |
| Net Income Before Taxes | 1343.18 | 1517.85 | 2461.42 | 1701.95 | 1241.2 |
| Net Income After Taxes | 1343.18 | 1517.85 | 2461.42 | 1701.95 | 1241.2 |
| Minority Interest | -133.155 | -140.126 | -112.884 | -726.914 | -621.473 |
| Net Income Before Extra. Items | 1210.03 | 1377.73 | 2348.53 | 975.04 | 619.728 |
| Net Income | 1210.03 | 1377.73 | 2348.53 | 975.04 | 619.728 |
| Income Available to Common Excl. Extra. Items | 1210.03 | 1377.73 | 2348.53 | 495.198 | 619.728 |
| Income Available to Common Incl. Extra. Items | 1210.03 | 1377.73 | 2348.53 | 495.198 | 619.728 |
| Diluted Net Income | 1210.03 | 1377.73 | 2348.53 | 495.198 | 619.728 |
| Diluted Weighted Average Shares | 595.383 | 595.383 | 595.383 | 375.455 | 414.802 |
| Diluted EPS Excluding Extraordinary Items | 2.03235 | 2.31402 | 3.94458 | 1.31893 | 1.49403 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0.3 | 0.68 |
| Diluted Normalized EPS | 1.94374 | 2.31402 | 3.94458 | 1.57329 | 1.49403 |
| Unusual Expense (Income) | 30.5 | ||||
| Total Adjustments to Net Income | -479.842 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Total revenue | 573.027 | 554.963 | 585.773 | 575.7 | 562.049 |
| Revenue | 573.027 | 554.963 | 585.773 | 575.7 | 562.049 |
| Total Operating Expense | 343.73 | -189.986 | 282.721 | 422.283 | 342.331 |
| Selling/General/Admin. Expenses, Total | 43.156 | 44.921 | 48.588 | 46.161 | 51.54 |
| Research & Development | 2.641 | 3.122 | 90.5 | 103.821 | 100.5 |
| Depreciation / Amortization | 5.671 | 5.733 | 5.796 | 5.796 | 5.67 |
| Other Operating Expenses, Total | 292.262 | -243.762 | 137.837 | 266.505 | 184.621 |
| Operating Income | 229.297 | 744.949 | 303.052 | 153.417 | 219.718 |
| Interest Income (Expense), Net Non-Operating | -70.361 | 61.913 | -80.463 | -94.926 | -89.878 |
| Other, Net | 0.043 | -0.107 | -0.793 | -4.82 | -1.757 |
| Net Income Before Taxes | 158.979 | 806.755 | 221.796 | 53.671 | 128.083 |
| Net Income After Taxes | 158.979 | 806.755 | 221.796 | 53.671 | 128.083 |
| Minority Interest | -89.86 | -365.979 | -119.867 | -45.767 | -76.322 |
| Net Income Before Extra. Items | 69.119 | 440.776 | 101.929 | 7.904 | 51.761 |
| Net Income | 69.119 | 440.776 | 101.929 | 7.904 | 51.761 |
| Income Available to Common Excl. Extra. Items | 69.119 | 440.776 | 101.929 | 7.904 | 51.761 |
| Income Available to Common Incl. Extra. Items | 69.119 | 440.776 | 101.929 | 7.904 | 51.761 |
| Diluted Net Income | 69.119 | 440.776 | 101.929 | 7.904 | 51.761 |
| Diluted Weighted Average Shares | 607.148 | 607.163 | 607.174 | 431.417 | 607.201 |
| Diluted EPS Excluding Extraordinary Items | 0.11384 | 0.72596 | 0.16787 | 0.01832 | 0.08525 |
| Dividends per Share - Common Stock Primary Issue | 0.17 | 0.17 | 0.17 | 0.17 | 0.19 |
| Diluted Normalized EPS | 0.11384 | 0.72596 | 0.16787 | 0.01832 | 0.08525 |
- Annual
- Quarterly
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Total Current Assets | 2608.55 | 832.072 | 2696.9 | 2878.21 | |
| Cash and Short Term Investments | 2386.03 | 793.214 | 2649.14 | 2803.27 | |
| Cash & Equivalents | 1924.21 | 283.682 | 1008.68 | 1541.05 | |
| Short Term Investments | 461.821 | 509.532 | 1640.46 | 1262.22 | |
| Total Receivables, Net | 198.627 | 38.766 | 39.166 | 68.309 | |
| Accounts Receivable - Trade, Net | 35.996 | 33.525 | 33.155 | 53.286 | |
| Other Current Assets, Total | 23.895 | 0.092 | 8.596 | 6.631 | |
| Total Assets | 11370.1 | 12449.9 | 16020.3 | 17515.9 | |
| Intangibles, Net | 75.648 | 51.724 | 28.666 | 5.67 | |
| Long Term Investments | 8666.83 | 11478.1 | 13266.1 | 14627.8 | |
| Other Long Term Assets, Total | 19.111 | 87.95 | 28.597 | 4.145 | |
| Total Current Liabilities | 580.172 | 333.417 | 307.887 | 171.25 | |
| Payable/Accrued | 4.477 | 11.177 | 10.775 | 5.62 | |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | |
| Current Port. of LT Debt/Capital Leases | 281.436 | 281.984 | 0 | ||
| Other Current Liabilities, Total | 294.259 | 40.256 | 144.966 | 107.934 | |
| Total Liabilities | 6881.93 | 6344.34 | 11201.5 | 11739.3 | |
| Total Long Term Debt | 6237.9 | 5956.14 | 5816.58 | 7096.07 | |
| Long Term Debt | 6237.9 | 5956.14 | 5816.58 | 7096.07 | |
| Minority Interest | 63.865 | 35.883 | 5077.04 | 4471.95 | |
| Other Liabilities, Total | 0 | 18.902 | 0 | ||
| Total Equity | 4488.21 | 6105.56 | 4818.78 | 5776.59 | |
| Common Stock | 3282.52 | 3282.52 | 0.10222 | 0.10617 | |
| Retained Earnings (Accumulated Deficit) | 1215.95 | 2825.21 | 1920.64 | 2255.18 | |
| Treasury Stock - Common | 0 | -4.266 | -2.317 | -2.715 | |
| Unrealized Gain (Loss) | -10.255 | 2.093 | 34.395 | 16.491 | |
| Total Liabilities & Shareholders’ Equity | 11370.1 | 12449.9 | 16020.3 | 17515.9 | |
| Total Common Shares Outstanding | 595.383 | 595.383 | 607.111 | 607.176 | |
| Accrued Expenses | 152.146 | 57.696 | |||
| Additional Paid-In Capital | 2865.96 | 3507.53 | |||
| Other Equity, Total | -0.00022 | -0.00017 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 2416.02 | 2707.45 | 2775.76 | 2878.21 | 2982.42 |
| Cash and Short Term Investments | 2369.37 | 2650.52 | 2693.31 | 2803.27 | 2911.22 |
| Cash & Equivalents | 708.81 | 1142.28 | 1800.81 | 1541.05 | 1791.52 |
| Short Term Investments | 1660.56 | 1508.24 | 892.507 | 1262.22 | 1119.7 |
| Total Receivables, Net | 39.995 | 44.837 | 73.501 | 68.309 | 65.808 |
| Accounts Receivable - Trade, Net | 33.454 | 34.143 | 59.657 | 53.286 | 51.19 |
| Other Current Assets, Total | 6.657 | 12.098 | 8.945 | 6.631 | 5.388 |
| Total Assets | 15914.1 | 16514.9 | 17732.4 | 17515.9 | 17378.9 |
| Intangibles, Net | 22.995 | 17.262 | 11.466 | 5.67 | 0 |
| Long Term Investments | 13467.9 | 13784.2 | 14940.6 | 14627.8 | 14392.6 |
| Other Long Term Assets, Total | 7.14 | 5.96 | 4.515 | 4.145 | 3.87 |
| Total Current Liabilities | 255.983 | 283.989 | 255.055 | 171.25 | 135.871 |
| Payable/Accrued | 8.272 | 9.393 | 9.187 | 5.62 | 6.662 |
| Accrued Expenses | 120.271 | 152.904 | 126.733 | 57.696 | 13.199 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 127.44 | 121.692 | 119.135 | 107.934 | 116.01 |
| Total Liabilities | 11031.9 | 10781.2 | 11939.3 | 11739.3 | 11601.3 |
| Total Long Term Debt | 5821.07 | 5825.56 | 7090.67 | 7096.07 | 7101.14 |
| Long Term Debt | 5821.07 | 5825.56 | 7090.67 | 7096.07 | 7101.14 |
| Minority Interest | 4954.82 | 4671.69 | 4593.56 | 4471.95 | 4364.32 |
| Total Equity | 4882.21 | 5733.68 | 5793.07 | 5776.59 | 5777.56 |
| Common Stock | 0.10221 | 0.10518 | 0.10618 | 0.10617 | 0.10617 |
| Additional Paid-In Capital | 2931.25 | 3415.6 | 3454.22 | 3507.53 | 3543.2 |
| Retained Earnings (Accumulated Deficit) | 1923.77 | 2291.97 | 2320.88 | 2255.18 | 2224.68 |
| Treasury Stock - Common | -2.359 | -2.662 | -2.685 | -2.715 | -2.736 |
| Other Equity, Total | 29.4518 | 28.6718 | 20.5528 | -0.00017 | 12.3038 |
| Total Liabilities & Shareholders’ Equity | 15914.1 | 16514.9 | 17732.4 | 17515.9 | 17378.9 |
| Total Common Shares Outstanding | 607.112 | 607.172 | 607.174 | 607.176 | 607.178 |
| Unrealized Gain (Loss) | 16.491 |
- Annual
- Quarterly
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Cash From Operating Activities | 1418.31 | 1618.32 | 1667.24 | 2034.63 | 2017.54 |
| Cash Receipts | 1870.16 | 2287.91 | 2105.2 | 2329.23 | 2545.79 |
| Cash Payments | -74.681 | -72.535 | -88.524 | -179.709 | -184.511 |
| Cash Interest Paid | -235.205 | -267.657 | -254.964 | -103.196 | -130.43 |
| Changes in Working Capital | -141.961 | -329.401 | -94.471 | -11.699 | -213.318 |
| Cash From Investing Activities | -1587.71 | 303.424 | -2116.14 | -2759.32 | -1870.28 |
| Capital Expenditures | -2290.71 | -269.593 | -1721.29 | -2182.25 | -2191.5 |
| Other Investing Cash Flow Items, Total | 703 | 573.017 | -394.851 | -577.074 | 321.222 |
| Cash From Financing Activities | -123.254 | -1379.1 | -1191.63 | 1487.17 | 385.112 |
| Financing Cash Flow Items | -1030.25 | -1085.1 | -897.626 | -989.716 | -602.237 |
| Issuance (Retirement) of Debt, Net | 907 | -294 | -294 | 680.634 | 1272.53 |
| Net Change in Cash | -292.648 | 542.64 | -1640.53 | 762.481 | 532.368 |
| Total Cash Dividends Paid | -112.49 | -285.184 | |||
| Issuance (Retirement) of Stock, Net | 1908.74 | 0 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Cash From Operating Activities | 526.1 | 1057.82 | 1527.58 | 2017.54 | 460.27 |
| Cash Receipts | 616.528 | 1194.85 | 1908.41 | 2545.79 | 674.716 |
| Cash Payments | -42.16 | -81.764 | -135.272 | -184.511 | -48.902 |
| Cash Interest Paid | -64.5 | -64.5 | -129.759 | -130.43 | -86.216 |
| Changes in Working Capital | 16.232 | 9.232 | -115.799 | -213.318 | -79.328 |
| Cash From Investing Activities | -599.3 | -473.134 | -1318.63 | -1870.28 | 11.165 |
| Capital Expenditures | -503.07 | -683.741 | -2019.77 | -2191.5 | -0.085 |
| Other Investing Cash Flow Items, Total | -96.23 | 210.607 | 701.134 | 321.222 | 11.25 |
| Cash From Financing Activities | -226.67 | -451.085 | 583.183 | 385.112 | -220.966 |
| Financing Cash Flow Items | -160.687 | -312.521 | -477.769 | -602.237 | -138.703 |
| Total Cash Dividends Paid | -65.983 | -138.564 | -211.581 | -285.184 | -82.263 |
| Issuance (Retirement) of Debt, Net | 0 | 0 | 1272.53 | 1272.53 | |
| Net Change in Cash | -299.87 | 133.601 | 792.128 | 532.368 | 250.469 |
| Issuance (Retirement) of Stock, Net | 0 | 0 | 0 |
Why choose Capital.com? Our numbers speak for themselves.
Capital.com Group 427000+
Traders
71000+
Active clients monthly
$46000000+
Monthly investing volume
$17000000+
Try now Withdrawn each month
Royalty Pharma plc Company profile
About Royalty Pharma plc
Royalty Pharma plc is engaged in investing in late stage biopharmaceutical products. The Company invests in academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The Company’s portfolio of pharmaceutical investment includes investments in commercial products and development-stage product candidates. Its portfolio investments include AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko, Trikafta and OXLUMO.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Royalty Pharma plc revenues increased 8% to $2.29B. Net income applicable to common stockholders increased 25% to $619.7M. Revenues reflect Income from financial royalty assets increase of 5% to $2.07B, Other royalty income increase from $19M to $53.1M, Revenue from intangible royalty assets increase of 19% to $171.2M. Net income benefited from Other operating expenses decrease from $65.1M (expense) to $0K.
| Industry: | Pharmaceuticals (NEC) |
110 East 59Th Street
10022
Income statement
News
GBP/USD analysis: UK inflation shock and gas crisis are here to stay - how will the pound perform?
UK inflation surpassed the double-digit threshold for the first time in 40 years. The pound faces pressures as UK gas prices trade at a record premium to US gas prices.
12:00, 17 August 2022
China slowdown: Could commodity currencies AUD and NZD be set for another losing streak?
New negative numbers from China is re-feeding recession anxiety as well as commodity currency pressure. What are the options?
11:33, 17 August 2022
Manchester United buyout: Elon Musk’s takeover ‘offer’ leaves MANU stock price unmoved
MANU stock price remained unmoved today despite Elon Musk tweet that he will buy the club.
11:00, 17 August 2022
Tornado Cash developer Pertsev arrested: Coders in firing line amid outrage over TORN sanctions
Crypto community decries TORN developer's arrest
10:32, 17 August 2022
Darktrace takeover: Thoma Bravo buyout firm’s DARK offer timing and details in full
Will others join Thoma Bravo and bid for Darktrace?
10:12, 17 August 2022People Also Watch
Bitcoin to US Dollar
23,394.45 Price
| Long position overnight fee | -0.0500% |
| Short position overnight fee | 0.0140% |
| Overnight fee time | 21:00 (UTC) |
| Spread | 60.00 |
Trade now
Still looking for a broker you can trust?
Join the 427.000+ traders worldwide that chose to trade with Capital.com
